Replimune Group, Inc.

Listed Company

REPLCIK 0001737953NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Mar 31

Period

FY 2026

Revenue

—

Net Income

—

Total Assets

$332.39M

Equity

$166.16M

Shares Out

83.95M

Op. Cash Flow

$-280.34M

REPL$10.24−18.19% · past yearDBEQ Basic

Daily closing prices

Business

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to activate the immune system against cancer by combining virus-mediated tumor cell killing with immune-stimulating payloads. The company's proprietary RPx platform, based on an engineered herpes simplex virus-1 backbone, includes lead candidate RP1 (in BLA review for advanced melanoma) and pipeline candidates RP2 and RP3 targeting additional tumor types. Replimune manufactures its product candidates in-house and intends to commercialize them directly in the United States and through partnerships internationally.

Summary from 10-K filed 2026-06-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Research and development	221	189	175	127	80
Selling, general and administrative	99	72	—	—	—
Total operating expenses	320	262	235	177	118
Loss from operations	−320	−262	−235	−177	−118
Research and development incentives	2	2	2	3	3
Investment income	14	21	23	10	390,000
Interest expense on finance lease liability	−2	−2	−2	−2	−2
Interest expense on debt obligations	−7	−6	−4	−2	0
Other expense	−942,000	−202,000	771,000	−6	−1
Total other income, net	5	15	19	3	278,000
Loss before income taxes	−314	−247	−215	−174	−118
Income tax (benefit) provision	−600,000	500,000	400,000	300,000	0
Net loss	−314	−247	−216	−174	−118
Net loss per common share, basic (in dollars per share)	−3.38	−3.07	−3.24	−2.99	−2.26
Net loss per common share, diluted (in dollars per share)	−3.38	−3.07	−3.24	−2.99	−2.26
Weighted average common shares outstanding, basic (in shares)	93	81	67	58	52
Weighted average common shares outstanding, diluted (in shares)	93	81	67	58	52

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Cash and cash equivalents	209	111	74	147	106
Short-term investments	60	373	346	437	290
Research and development incentives receivable	2	4	5	3	3
Prepaid expenses and other current assets	9	8	8	6	5
Total current assets	279	496	434	593	404
Property, plant and equipment, net	13	14	10	7	8
Restricted cash	2	2	2	2	2
Other non-current assets	3	1	0	—	—
Right-of-use assetoperating leases	3	4	5	5	6
Right-of-use assetfinance leases	32	35	37	40	42
Total assets	332	551	488	647	461
Accounts payable	7	12	3	5	4
Accrued expenses and other current liabilities	48	46	34	25	13
Operating lease liabilities, current	1	1	1	1	1
Finance lease liabilities, current	3	3	3	3	3
Total current liabilities	58	62	40	34	21
Operating lease liabilities, non-current	2	3	4	4	5
Finance lease liabilities, non-current	22	23	23	24	24
Long term debt, net of discount	83	46	45	29	0
Other liabilities, non-current	455,000	941,000	786,000	472,000	0
Total liabilities	166	135	113	91	50
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2026 and March 31, 2025; 82,716,923 and 77,085,024 shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively	82,000	77,000	61,000	57,000	47,000
Additional paid-in capital	1,423	1,359	1,071	1,035	723
Accumulated deficit	−1,263	−949	−701	−485	−311
Accumulated other comprehensive income	5	5	5	6	−973,000
Total stockholders equity	166	416	375	555	411
Total liabilities and stockholders equity	332	551	488	647	461

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Net loss	−314	−247	−216	−174	−118
Stock-based compensation expense	32	35	34	28	24
Depreciation and amortization	3	4	3	2	2
Operating lease, right-of-use-asset amortization	771,000	683,000	—	—	—
Finance lease, right-of-use-asset amortization	2	2	—	—	—
Net amortization of premiums and discounts on short-term investments	−3	−9	−12	−6	2
Impairment on property, plant and equipment	188,000	0	—	—	—
Noncash interest expense	2	2	1	494,000	0
Unrealized foreign currency transaction gains	−942,000	−201,000	−771,000	6	0
Research and development incentives receivable	451,000	1	−2	−61,000	−247,000
Prepaid expenses and other current assets	−232,000	−252,000	−2	−1	−815,000
Other non-current assets	0	−1	0	—	—
Accounts payable	−5	10	−3	2	1
Accrued expenses and other current liabilities	2	12	9	11	5
Operating lease liabilities	−818,000	−720,000	−620,000	−238,000	−73,000
Other non-current liabilities	−487,000	155,000	314,000	472,000	0
Net cash used in operating activities	−280	−192	−185	−128	−82
Purchases of property, plant and equipment and software capitalization	−4	−7	−6	−2	—
Purchase of short-term investments	−78	−404	−490	−583	−256
Proceeds from sales and maturities of short-term investments	393	386	592	443	256
Net cash provided by (used in) investing activities	311	−24	97	−143	−2
Proceeds from issuance of prefunded warrants to purchase common stock, net of underwriting fees and offering costs	0	97	0	93	0
Proceeds from long-term debt	35	0	15	28	0
Principal payment of finance lease obligation	−736,000	−599,000	−476,000	−365,000	−264,000
Proceeds from exercise of stock options and pre-funded warrants	883,000	267,000	2	3	7
Net cash provided by financing activities	66	252	16	311	7
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1	315,000	−86,000	−109,000	818,000
Net increase in cash, cash equivalents and restricted cash	98	37	−72	41	−77
Cash paid during the period for interest	5	4	3	1	0
Cash received (paid) for income taxes, net	5,000	−105,000	300,000	0	55,000
Purchases of property and equipment included in accounts payable and accrued expenses	80,000	171,000	101,000	103,000	415,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Replimune Group, Inc.'s CIK number?

Replimune Group, Inc.'s SEC CIK number is 0001737953 (1737953). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Replimune Group, Inc.'s SEC filings?

All of Replimune Group, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Replimune Group, Inc. last report earnings?

Replimune Group, Inc. (REPL) most recently filed an earnings 8-K with the SEC on Jun 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-078511). This is Replimune Group, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Replimune Group, Inc.'s most recent earnings 8-K?

Replimune Group, Inc.'s latest earnings 8-K (Item 2.02) was filed Jun 29, 2026 under accession 0001104659-26-078511. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Replimune Group, Inc.'s latest earnings 8-K →
Look up any company's CIK number →